Home » Regions » Global News » Schrödinger and ChemAxon extend partnership

Schrödinger and ChemAxon extend partnership

Thursday, July 11, 2013

Schrödinger, a drug discovery solutions company, and ChemAxon, a provider of cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries, have extended their partnership agreement for another five years. ChemAxon will provide the JChem chemistry engine as well as Marvin sketching and rendering functionality to Schrödinger’s enterprise informatics platform, Seurat.

A data integration and discovery collaboration platform, Seurat provides decision and project support as well as advanced data exploration, and can consume backend data or replace legacy tools like Accord, ISIS, Isentris or internally-developed customer tools that have reached end of life. Seurat can be installed locally or hosted on either the British Telecom (BT) or Amazon Web Services (AWS) cloud.

“Its long-term nature demonstrates that collaboration between partners with complementary technologies is a sustainable business model in our sector, and can offer a better solution to customers and a more efficient development environment for partners,” said Alex Drijver, chief executive officer of ChemAxon.

ChemAxon’s JChem chemistry engine, able to be deployed universally and scale to cover big data requirements, is a chemical structure storage and search toolkit. Also included in the provision is the JKlustor functionality for high performance structure library analysis as well as the Marvin editor & viewer which lets users ask chemical questions and see structures as answers.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!